专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006109086A2 METHOD 审中-公开
标题翻译：方法
公开(公告)号：WO2006109086A2
公开(公告)日：2006-10-19
申请号：PCT/GB2006/001384
申请日：2006-04-13
申请人： ASTRAZENECA AB , ASTRAZENECA UK LIMITED , RONCO, Lucienne , WEBSTER, Kevin , YU, Lihua , ZHANG, Xiaolin
发明人： RONCO, Lucienne , WEBSTER, Kevin , YU, Lihua , ZHANG, Xiaolin
IPC分类号： G01N33/50 , A61K47/42 , A61K47/48 , C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , G01N33/57407 , G01N2800/52
摘要： The invention includes a method of selecting a mammal having or suspected of having a tumor for treatment with an Eg5 inhibitor drug, the method comprising providing a biological sample from a subject having cancer and testing the biological sample for expression of any one of the genes listed in Tables 1, 2 and 5, or their gene products, thereby to predict an increased likelihood of response to the Eg5 inhibitor drug.
摘要翻译：本发明包括选择具有或怀疑具有用于用Eg5抑制剂药物治疗的肿瘤的哺乳动物的方法，所述方法包括从具有癌症的受试者提供生物样品并测试所述生物样品以表达所列出的任何一种基因在表1,2和5中，或其基因产物，从而预测对Eg5抑制剂药物的反应可能性增加。

2. 发明申请

WO2014135876A1 QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR 审中-公开
标题翻译：激活生长因子受体突变形式的喹唑啉抑制剂
公开(公告)号：WO2014135876A1
公开(公告)日：2014-09-12
申请号：PCT/GB2014/050655
申请日：2014-03-05
申请人： ASTRAZENECA AB , ASTRAZENECA UK LIMITED
发明人： LI, David, Yunzhi , WANG, Jiabing , YANG, Zhenfan , ZENG, Qingbei , ZHANG, Xiaolin
IPC分类号： C07D403/12 , A61K31/495 , A61K31/505
CPC分类号： A61K31/517 , A61K31/4184 , A61K31/4985 , A61K31/519 , A61K39/3955 , A61K45/06 , C07D403/12 , A61K2300/00
摘要： The invention relates to compounds of formula(I), or a pharmaceutically acceptable salt thereof: Formula (I) which possess inhibitory activity against activating mutant forms of EGFR,and are accordingly useful for their anti-cancer activity and in methods of treatment of the human or animal body. The invention also relates pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti- cancer effect in a warm-blooded animal such as man.
摘要翻译：本发明涉及式（I）化合物或其药学上可接受的盐：具有抑制活化突变形式的EGFR的抑制活性的式（I），因此可用于其抗癌活性和治疗方法人或动物体。本发明还涉及含有它们的药物组合物及其在制造用于在温血动物如人中产生抗癌作用的药物中的用途。

3. 发明申请

WO2019215268A1 CYCLOPENTANE COMPOUNDS 审中-公开
公开(公告)号：WO2019215268A1
公开(公告)日：2019-11-14
申请号：PCT/EP2019/061888
申请日：2019-05-09
申请人： ASTRAZENECA AB , ZHANG, Xiaolin
发明人： ZHANG, Xiaolin , PAN, Weitao , NIKITIDIS, Grigorios , LINDHAGEN, Jenny, Susanna, Marika
IPC分类号： C07D401/08 , C07D211/56 , A61P13/12 , A61K31/451 , A61K31/454 , A61K31/4545
摘要： The present invention relates to cyclopentane compounds of Formula (I), physical forms thereof, processes for their production and their use in medicine.

4. 发明申请

WO2017117357A1 SYSTEM AND METHOD FOR DATA SECURITY 审中-公开
标题翻译：用于数据安全的系统和方法
公开(公告)号：WO2017117357A1
公开(公告)日：2017-07-06
申请号：PCT/US2016/069128
申请日：2016-12-29
申请人： ZHANG, Xiaolin
发明人： ZHANG, Xiaolin
IPC分类号： H04L9/32
CPC分类号： H04L9/3247 , H04L63/126
摘要： A system of securely sharing data includes first and second computers connected to a network and first and second non-transitory computer-readable media. Each computer includes a respective processor and network controller for transmitting and receiving a signature file and a data file across the network. The computer-readable media are each connected to a respective processor. Each computer-readable media stores certification instructions that, when executed, perform the steps of a certification process on the signature and data files. The certification process includes utilizing the first computer and certification instructions to create and transmit, to the second computer, a signature file related to the data file, and utilizing the second computer and certification instructions to receive and analyze the signature file to certify the data file for processing. The signature file includes objective meta-data based on information in the data file, specification data regarding executable instructions in the data file, or both.
摘要翻译：一种安全共享数据的系统包括连接到网络的第一和第二计算机以及第一和第二非暂时性计算机可读介质。每台计算机都包括一个相应的处理器和网络控制器，用于通过网络发送和接收签名文件和数据文件。计算机可读介质各自连接到相应的处理器。每个计算机可读介质存储认证指令，所述认证指令在被执行时对签名和数据文件执行认证过程的步骤。认证过程包括利用第一计算机和认证指令来创建并传输与第二计算机有关的数据文件的签名文件，以及利用第二计算机和认证指令来接收和分析签名文件以认证数据文件进行处理。签名文件包括基于数据文件中的信息的客观元数据，与数据文件中的可执行指令有关的指定数据，或两者。

5. 发明申请

WO2008003100A2 MAKE AND USE OF SURFACE MOLECULES OF VARIED DENSITIES 审中-公开
标题翻译：不同密度的表面分子的制作和使用
公开(公告)号：WO2008003100A2
公开(公告)日：2008-01-03
申请号：PCT/US2007/072609
申请日：2007-06-29
申请人： GAO, Xiaolian , ZHOU, Xiaochuan , ZHANG, Xiaolin , HONG, Ailing , ZHU, Qi , YU, Peilin
发明人： GAO, Xiaolian , ZHOU, Xiaochuan , ZHANG, Xiaolin , HONG, Ailing , ZHU, Qi , YU, Peilin
IPC分类号： B05D5/02
CPC分类号： G01N33/54353 , B01J19/0046 , B01J2219/00454 , B01J2219/005 , B01J2219/00527 , B01J2219/00576 , B01J2219/00585 , B01J2219/00592 , B01J2219/00596 , B01J2219/00605 , B01J2219/00626 , B01J2219/00648 , B01J2219/00659 , B01J2219/00675 , B01J2219/00677 , B01J2219/0072 , B01J2219/00722 , B01J2219/00725 , B82Y30/00 , C07B2200/11 , C40B40/04 , C40B50/14 , G01N33/6803 , G01N33/6842
摘要： The present invention relates to quantitative and quantity aspects of array synthesis and array uses as a device for high capacity producing synthetic moiecuies for off-array surface applications and as an assay device for on-array surface applications.
摘要翻译：本发明涉及阵列合成和阵列用途的定量和数量方面，作为用于大量生产用于非阵列表面应用的合成模块的装置和用于阵列表面应用的测定装置。

6. 发明申请

WO2004039953A3 ARRAY OLIGOMER SYNTHESIS AND USE. 审中-公开
公开(公告)号：WO2004039953A3
公开(公告)日：2004-05-13
申请号：PCT/US2003/034207
申请日：2003-10-28
申请人： XEOTRON CORPORATION , GAO, Xiaolian , ZHOU, Xiaochuan , CAI, Shi-Ying , YU, Qimin , ZHANG, Xiaolin
发明人： GAO, Xiaolian , ZHOU, Xiaochuan , CAI, Shi-Ying , YU, Qimin , ZHANG, Xiaolin
IPC分类号： C12Q1/68
摘要： The present disclosure provides efficient and reproducible methods for individually synthesizing oligomers in a parallel manner (e.g., oligonucleotides) on a solid support to produce pools of oligomers. Pools of oligonucleotides can be used for a variety of genomic and proteomic applications, including synthesis of genes or long DNA of any arbitrary sequence, PCR template amplification, and to generate primers for multiplexing PCR or transcription. Rapid availability of these oligonucleotide products will greatly accelerate the processes of de novo protein design, vaccine development, production of short RNA fragments, such as siRNA, oligonucleotide-based drug screening, and SNP sample preparation.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式